A recent study has shown that NTLA-2002, an experimental gene editing treatment for hereditary angioedema (HAE), significantly reduced the frequency of swelling attacks in patients.

Bio-Thera Solutions has initiated a Phase IA/IIA clinical trial for BAT6026, a monoclonal antibody designed to target OX40.

Therapeutic company Theradaptive has received approval from the U.S. FDA to initiate a global Phase I/II study for its spinal fusion product, OsteoAdapt SP.

Sirius Therapeutics has initiated a Phase 1 clinical trial for SRSD107, an innovative siRNA treatment aimed at preventing and managing thromboembolic disorders by targeting coagulation Factor XI (FXI).

The first individual has been administered TH104 in a Phase 1 clinical trial, focusing on the drug's safety, tolerability, and absolute bioavailability.

Sangamo Therapeutics has reported positive interim results from its Phase 1/2 STAAR clinical trial for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease.

ProLynx Inc. initiated a Phase I/II clinical study involving PLX038, a PEGylated form of SN-38, for treating primary central nervous system (CNS) tumors with MYC or MYCN gene amplifications.

ProfoundBio has launched the Phase 1/2 clinical trial for PRO1107, marking a significant step in their mission to enhance patient outcomes.

Rani Therapeutics Holdings, Inc. reported encouraging topline results from its Phase 1 clinical trial of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar (CT-P43).

This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells.

In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.

Recent advancements in Alzheimer's treatment are promising, with Biogen and Eisai's Leqembi receiving full approval in July, and EliLilly's donanemab potentially following suit soon.